# Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

> **NCT06368726** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Citlalli Mellado Balanzar** · enrollment: 180 (estimated)

## Conditions studied

- Attention
- Visual Perceptual Weakness
- Social Behavior
- Fluency Disorder
- EEG With Periodic Abnormalities

## Interventions

- **DEVICE:** tDCS or Transcranial Direct Current Stimulation
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT06368726
- **Lead sponsor:** Citlalli Mellado Balanzar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-01
- **Primary completion:** 2025-12-12
- **Final completion:** 2026-06-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06368726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06368726, "Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06368726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*